Vividion Therapeutics’ proteomics screening platform and small molecule library will be leveraged by the San Diego-based company and Roche to target novel E3 ligases in addition to a variety of oncology and immunology therapy targets.
Bayer and biotechnology company Dewpoint Therapeutics announced an option, research and license agreement worth up to $100 million.
Cambridge, Mass.-based HotSpot Therapeutics burst forth from stealth mode with $45 million in Series A funding to support the development of therapies that will target natural “regulatory hotspots.”
Kymera Therapeutics launched with a $30 million Series A financing. The round was led by Atlas Venture, which co-founded, seeded and incubated the company, along with Lilly Ventures and Amgen Ventures.